Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CADL Candel Therapeutics	$6.57 -2.5%	$5.48	$3.79 ▼ $14.60	$337.69M	-0.91	1.51 million shs	744,597 shs
CNTB Connect Biopharma	$2.00 +16.3%	$0.99	$0.51 ▼ $2.20	$95.57M	-0.2	67,901 shs	363,246 shs
NGNE Neurogene	$21.66 -3.0%	$19.15	$6.88 ▼ $74.49	$318.61M	1.51	252,043 shs	116,250 shs
TNXP Tonix Pharmaceuticals	$45.10 -3.9%	$35.20	$6.76 ▼ $130.00	$345.13M	2.05	1.01 million shs	1.92 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CADL Candel Therapeutics	-2.52%	+2.18%	+38.32%	+38.61%	+9.32%
CNTB Connect Biopharma	+16.28%	+41.84%	+94.17%	+185.80%	+57.48%
NGNE Neurogene	-3.04%	-2.70%	+21.96%	+56.62%	-48.75%
TNXP Tonix Pharmaceuticals	-3.86%	+5.42%	+39.37%	+201.47%	-19.49%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CADL Candel Therapeutics	2.5365 of 5 stars	3.6	1.0	3.3	1.7	0.6
CNTB Connect Biopharma	2.0561 of 5 stars	3.5	3.0	0.6	2.5	0.0
NGNE Neurogene	3.0864 of 5 stars	4.4	2.0	0.0	1.7	0.6
TNXP Tonix Pharmaceuticals	2.2168 of 5 stars	3.5	2.0	0.0	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CADL Candel Therapeutics	3.20	Buy	$22.00	234.86% Upside
CNTB Connect Biopharma	3.00	Buy	$7.00	250.00% Upside
NGNE Neurogene	2.75	Moderate Buy	$46.17	113.14% Upside
TNXP Tonix Pharmaceuticals	3.00	Buy	$70.00	55.21% Upside

Current Analyst Ratings Breakdown

Latest CNTB, NGNE, CADL, and TNXP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/9/2025	CADL Candel Therapeutics	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/30/2025	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$23.00
6/17/2025	NGNE Neurogene	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00
6/12/2025	CNTB Connect Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$7.00
6/12/2025	NGNE Neurogene	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$22.00 ➝ $26.00
6/3/2025	TNXP Tonix Pharmaceuticals	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/20/2025	NGNE Neurogene	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$16.00 ➝ $22.00
5/16/2025	NGNE Neurogene	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	NGNE Neurogene	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$38.00 ➝ $24.00
5/13/2025	NGNE Neurogene	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $45.00

(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CADL Candel Therapeutics	$120K	2,742.98	N/A	N/A	$1.41 per share	4.66
CNTB Connect Biopharma	$26.03M	4.27	N/A	N/A	$1.67 per share	1.20
NGNE Neurogene	$930K	332.12	N/A	N/A	$20.89 per share	1.04
TNXP Tonix Pharmaceuticals	$10.09M	32.90	N/A	N/A	$31.82 per share	1.42

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CADL Candel Therapeutics	-$55.18M	-$1.34	N/A	N/A	N/A	N/A	-136.74%	-63.13%	8/12/2025 (Estimated)
CNTB Connect Biopharma	-$15.63M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/5/2025 (Estimated)
NGNE Neurogene	-$75.14M	-$4.35	N/A	N/A	N/A	N/A	-36.16%	-32.51%	8/8/2025 (Estimated)
TNXP Tonix Pharmaceuticals	-$130.04M	-$1,963.61	0.00	N/A	N/A	-1,313.87%	-120.96%	-101.28%	8/15/2025 (Estimated)

Latest CNTB, NGNE, CADL, and TNXP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/15/2025	Q1 2025	TNXP Tonix Pharmaceuticals	-$6.71	N/A	N/A	N/A	$2.60 million	N/A
8/12/2025	Q2 2025	CADL Candel Therapeutics	-$0.17	N/A	N/A	N/A	N/A	N/A
8/8/2025	Q2 2025	NGNE Neurogene	-$1.15	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	CNTB Connect Biopharma	-$0.26	-$0.19	+$0.07	-$0.19	N/A	N/A
5/13/2025	Q1 2025	CADL Candel Therapeutics	-$0.24	$0.13	+$0.37	$0.13	N/A	N/A
5/12/2025	Q1 2025	TNXP Tonix Pharmaceuticals	-$3.23	-$2.84	+$0.39	-$2.84	$2.55 million	$2.43 million
5/9/2025	Q1 2025	NGNE Neurogene	-$1.05	-$1.08	-$0.03	-$1.08	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
CNTB Connect Biopharma	N/A	N/A	N/A	N/A	N/A
NGNE Neurogene	N/A	N/A	N/A	N/A	N/A
TNXP Tonix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CADL Candel Therapeutics	0.01	4.64	4.64
CNTB Connect Biopharma	0.01	10.25	10.25
NGNE Neurogene	N/A	21.03	21.03
TNXP Tonix Pharmaceuticals	N/A	12.31	11.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CADL Candel Therapeutics	13.93%
CNTB Connect Biopharma	58.72%
NGNE Neurogene	52.37%
TNXP Tonix Pharmaceuticals	82.26%

Insider Ownership

Company	Insider Ownership
CADL Candel Therapeutics	16.60%
CNTB Connect Biopharma	22.60%
NGNE Neurogene	9.92%
TNXP Tonix Pharmaceuticals	0.03%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CADL Candel Therapeutics	60	50.10 million	41.79 million	Optionable
CNTB Connect Biopharma	110	55.56 million	43.00 million	Optionable
NGNE Neurogene	90	14.26 million	12.85 million	Optionable
TNXP Tonix Pharmaceuticals	50	7.36 million	7.36 million	Not Optionable

CNTB, NGNE, CADL, and TNXP Headlines

Recent News About These Companies

Tonix Pharmaceuticals Announces the Launch of the “Move Fibro Forward” Campaign to Bring Awareness to Individuals Impacted by Fibromyalgia

July 21 at 7:00 AM | globenewswire.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Crosses Above Two Hundred Day Moving Average - Should You Sell?

July 19 at 5:17 AM | marketbeat.com

Tonix Pharma Plans Sales Force for TNX-102 SL

July 16, 2025 | tipranks.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 5.8% - Time to Sell?

July 11, 2025 | marketbeat.com

Tonix up after peer reviewed data for pain therapy and new data for mpox vaccine

July 10, 2025 | msn.com

Tonix Pharmaceuticals Shares Climb on Encouraging TNX-801 Vaccine Results

July 10, 2025 | msn.com

Tonix Pharmaceuticals (TNXP) Surges 10% on Phase 3 Data Release

July 10, 2025 | gurufocus.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Up 11.4% - Should You Buy?

July 10, 2025 | marketbeat.com

Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate ...

July 10, 2025 | gurufocus.com

Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate ...

July 10, 2025 | gurufocus.com

Tonix Pharmaceuticals (TNXP) Unveils Promising TNX-801 Vaccine Data | TNXP Stock News

July 10, 2025 | gurufocus.com

Tonix Pharma Unveils Promising TNX-801 Vaccine Findings

July 10, 2025 | tipranks.com

Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025

July 10, 2025 | globenewswire.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Trading 6.5% Higher - Here's Why

July 9, 2025 | marketbeat.com

Tonix Pharma Publishes Phase 3 Trial Results

July 9, 2025 | tipranks.com

Tonix Pharmaceuticals Announces Publication of Positive Phase 3 RESILIENT Trial Data for TNX-102 SL in Fibromyalgia Management

July 9, 2025 | quiverquant.comQ

Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine

July 9, 2025 | globenewswire.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 2.5% - Here's Why

July 7, 2025 | marketbeat.com

Tonix Pharmaceuticals Announces Efficacy and Safety of Single-Dose TNX-801 Vaccine Against Monkeypox

July 7, 2025 | quiverquant.comQ

Tonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025

July 7, 2025 | globenewswire.com

TNXP Tonix Pharmaceuticals Holding Corp. - Seeking Alpha

July 4, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTB, NGNE, CADL, and TNXP Company Descriptions

Candel Therapeutics NASDAQ:CADL

$6.57 -0.17 (-2.52%)

Closing price 07/21/2025 04:00 PM Eastern

Extended Trading

$6.62 +0.05 (+0.84%)

As of 07/21/2025 07:45 PM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Connect Biopharma NASDAQ:CNTB

$2.00 +0.28 (+16.28%)

Closing price 07/21/2025 04:00 PM Eastern

Extended Trading

$1.98 -0.02 (-1.25%)

As of 07/21/2025 07:58 PM Eastern

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

Neurogene NASDAQ:NGNE

$21.66 -0.68 (-3.04%)

Closing price 07/21/2025 04:00 PM Eastern

Extended Trading

$21.68 +0.02 (+0.12%)

As of 07/21/2025 07:01 PM Eastern

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

Tonix Pharmaceuticals NASDAQ:TNXP

$45.10 -1.81 (-3.86%)

Closing price 07/21/2025 04:00 PM Eastern

Extended Trading

$45.56 +0.46 (+1.02%)

As of 07/21/2025 07:59 PM Eastern

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time